| Study of Lonafarnib in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck (Study P02530) (NCT00073450) | Merck Sharp & Dohme LLC | 2003-09-01 |
| Feasibility Study of Incorporating 18F-FDG-PET Imaging in Radiotherapy for Head and Neck Cancer (NCT00135161) | University Hospital, Ghent | 2003-09-01 |
| Docetaxel in Squamous Cell Carcinoma of the Head and Neck (TAX + Cisplatin in SCCHN) (NCT00268671) | Sanofi | 2003-08-01 |
| The Role of CT-PET-MRI Image Fusion in Determining Radiation Treatment Volumes of Head-and-Neck Cancer Patients (NCT00184860) | Radboud University Medical Center | 2003-06-01 |
| Gefitinib (Iressa) in Combo With Chemoradiation in Patients With Locally Advanced Head & Neck Cancer (NCT00239304) | AstraZeneca | 2003-06-01 |
| Study of Intralesional Injection of M4N in Patients With Refractory Malignant Tumors of the Head and Neck (NCT00057512) | Erimos Pharmaceuticals | 2003-01-01 |
| Neoadjuvant Docetaxel Plus Cisplatin and 5-fluorouracil (TPF) Followed by Concomitant Chemoradiotherapy and Chemoradiotherapy Alone in Locally Advanced Squamous Cell Carcinoma of the Head and Neck Patients (SCCHNS) (NCT00357149) | Sanofi | 2003-01-01 |
| Docetaxel in Head and Neck Cancer (NCT00261703) | Sanofi | 2002-12-01 |
| Molecular and Genomic Profiling of Head and Neck Tumors (NCT00200486) | Montefiore Medical Center | 2002-10-01 |
| Concomitant Radiation and Cisplatin With and Without Tirapazamine in Treatment of Advanced Head and Neck Cancer (NCT00094081) | Sanofi | 2002-10-01 |
| Single Dose Escalation Study of Bivatuzumab Mertansine in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck (NCT02254018) | Boehringer Ingelheim | 2002-09-01 |
| NPC Study : TAX + CIS Neoadjuvant in Patients With Loco Regionally Advanced Undifferentiated Carcinoma of Nasopharyngeal Type (UCNT) (NCT00916097) | Sanofi | 2002-07-01 |
| Study of Combination Docetaxel and Radiotherapy With or Without Cisplatin to Treat Local Advanced Head and Neck Cancer (NCT00521521) | Sanofi | 2001-07-01 |
| Patient Evaluation for Head and Neck Surgery Branch Studies (NCT00011492) | National Institute on Deafness and Other Communication Disorders (NIDCD) | 2001-03-12 |
| Porfiromycin Used as an Adjuvant to Radiation Therapy in Postoperative Head and Neck Cancer Patients (NCT02183246) | Boehringer Ingelheim | 2000-05-01 |
| Pharmacokinetic Study of Porfiromycin in Head and Neck Cancer and Other Cancer Patients With Solid Tumors (NCT02209701) | Boehringer Ingelheim | 1999-12-01 |
| Mouth Care Regimes During Radiotherapy (NCT00138827) | St George Hospital, Australia | 1999-11-01 |
| Dose Escalation Study With 99mTC - or 186 Re-labelled Humanised Monoclonal Antibody (hMAb) BIWA 4 in Patients With Head and Neck Cancer (NCT02204033) | Boehringer Ingelheim | 1999-03-01 |
| Assessment of Head and Neck Tumor Hypoxia Using 18F-Fluoromisonidazole (NCT00038038) | M.D. Anderson Cancer Center | 1994-01-01 |
| An Imaging Study in Patients With Thyroid Cancer or Head and Neck Cancer With Pertechnetate Made in a Cyclotron (C-PERT) (NCT01747512) | AHS Cancer Control Alberta | |
| Phase II Trial of Allovectin-7® for Head and Neck Cancer (NCT00050388) | Vical | |
| Radiotherapy, Cetuximab, and Injections of TNFerade™ Biologic for Elderly or Frail Patients With Head and Neck Cancer (NCT00496236) | GenVec | |
| A Study of Conventional 3D Radiation vs. Intensity-Modulated Radiation in Squamous Cell Cancer of the Head and Neck (NCT00363441) | Alberta Health services | |
| A Study of TNFerade™ Biologic With Concomitant Radiotherapy, Fluorouracil, and Hydroxyurea (TNF-FHX) in Patients With Head and Neck Cancer (NCT00496535) | GenVec | |
| Expanded Access [11C] Methionine PET Imaging (NCT05511714) | St. Jude Children's Research Hospital | |